Medivation (MDVN) Skyrockets As Prostate Cancer Drug Proven Effective

Article Stock Quotes (1) Comments (0)

Shares of Medivation, Inc. (Nasdaq: MDVN) have more than doubled early Thursday after the company and partner Astellas Pharma said the Independent Data Monitoring Committee (IDMC) informed them of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer.

MDV3100 successfully met the study's pre-specified interim efficacy stopping criteria, demonstrating a clinically meaningful and statistically significant (p < 0.0001) improvement in overall survival compared to placebo.

As a result of the positive results, the IDMC recommended the study be stopped early and men who received placebo be offered MDV3100.

The stock last traded at $37.25, up 127 percent from Wednesday's close.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Sony (SNE) is Early Winner in Battle of Video Game Giants (MSFT)
• Molycorp (MCP) Continues Recent Surge Higher; Fundamentals Come Into Play
• Hologic (HOLX) Announces FDA Approval of C-View 2D Imaging for or Breast Cancer Screening

Create E-mail Alert Related Categories

FDA, Momentum Movers

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?